이식형 포트 시장(-2035년) : 재료 유형, 용도, 삽입 방법, 지역별

Global Implantable Port Market Research Report By Material Type (Silicone, Polyurethane, Titanium), By Application (Chemotherapy, Antibiotic Therapy, Total Parenteral Nutrition, Blood Transfusion), By Insertion Method (Surgical Insertion, Percutaneous Insertion) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

Overview of the Market

The size of the implantable port market was projected to be USD 3,290.28 million in 2024 based on MRFR analysis. The market for implantable ports is anticipated to develop at a compound annual growth rate (CAGR) of 6.21% between 2025 and 2035.

Growing rates of chronic illnesses are fueling the market for implantable ports by raising need for long-term intravenous access options. Implantable ports are becoming more and more popular as medical professionals concentrate on improving patient comfort and treatment efficacy. Demand is further increased by the expansion of home healthcare and outpatient settings, which need dependable and efficient ways to provide medication. Furthermore, improvements in medical technology guarantee stronger, safer implants, which propels market expansion. The creation of materials that enhance biocompatibility and reduce the risk of infection is one business opportunity that will open the door for more creative implantable port designs. Digital health technology, such remote monitoring systems, can be used to enhance patient management as the focus on patient-centric care grows. Increasing healthcare professionals' knowledge of implantable ports' advantages can further spur market expansion, particularly in poorer nations where adoption of these technologies is still in its infancy. Recent trends show a move toward less intrusive procedures, which increases the appeal of implantable ports for both patients and medical professionals. To enhance the functionality and design of these gadgets, manufacturers and physicians are increasingly working together.

Perspectives on Market Segments

The global market for implantable ports has been divided into three segments based on material type: silicone, titanium, and polyurethane.

The global implantable port market has been divided into four segments based on application: blood transfusion, chemotherapy, antibiotic therapy, and total parenteral nutrition.

The worldwide market for implantable ports has been divided into two segments based on the manner of insertion: percutaneous and surgical. The market segment with the quickest rate of growth over the forecast period is surgical insertion, which held the biggest market share in 2024.

Regional Perspectives

North America, Europe, Asia-Pacific, South America, and the Middle East & Africa are the regions into which the global implantable port market has been divided. The greatest market share in 2024 was held by North America, which is expected to grow to USD 2,416.61 million by 2035. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 8.32%.

The implantable port market in North America was valued at USD 1,382.75 million in 2024 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.20% over the course of the forecast period. The United States and Canada are two more divisions of North America.

The market for implanted ports in Europe was valued at USD 972.35 million in 2024 and is anticipated to expand at a compound annual growth rate (CAGR) of 6.41% over the course of the forecast period. Germany, France, the United Kingdom, Italy, Spain, Russia, and the rest of Europe are further divisions of Europe.

Key Players

Easton Medical, Baxter International, Zyga Technology, Terumo, Apex Medical Technologies, Medtronic, Boston Scientific, Cook Medical, AngioDynamics, Kirwan Surgical Products, Smiths Medical, Nitinol Devices Corporation, C R Bard, Stryker, and Halyard Health are some of the major players in the implantable port market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
• 1.2 MARKET ATTRACTIVENESS ANALYSIS
• 1.3 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE
• 1.4 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION
• 1.5 GLOBAL IMPLANTABLE PORT MARKET, BY END USER
• 1.6 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD
• 1.7 GLOBAL IMPLANTABLE PORT MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research Data Flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.5.3 Primary Research: Regional Coverage
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 Microeconomic Factor Analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Increasing Incidences of Chronic Diseases across the globe
  • 4.2.2 Technological Advancements
  • 4.2.3 Better Healthcare Access
• 4.3 RESTRAINTS
  • 4.3.1 High Cost of Implantation
  • 4.3.2 Surgical Risks
• 4.4 OPPORTUNITY
  • 4.4.1 Expansion in Emerging Markets
  • 4.4.2 Growing Aging Population

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 Manufacturing
  • 5.1.3 Marketing and Distribution & Channel
  • 5.1.4 Post-market Surveillance
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 Threat of New Entrants
  • 5.2.2 Bargaining Power of Suppliers
  • 5.2.3 Threat of Substitutes
  • 5.2.4 Bargaining Power of Buyers
  • 5.2.5 Intensity of Rivalry
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL IMPLANTABLE PORT MARKET

6 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE

• 6.1 OVERVIEW
• 6.2 SILICONE
• 6.3 POLYURETHANE
• 6.4 TITANIUM

7 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 CHEMOTHERAPY
• 7.3 ANTIBIOTIC THERAPY
• 7.4 TOTAL PARENTERAL NUTRITION
• 7.5 BLOOD TRANSFUSION

8 GLOBAL IMPLANTABLE PORT MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS
• 8.3 AMBULATORY SURGICAL CENTERS
• 8.4 SPECIALIZED CLINICS

9 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD

• 9.1 OVERVIEW
• 9.2 SURGICAL INSERTION
• 9.3 PERCUTANEOUS INSERTION

10 GLOBAL IMPLANTABLE PORT MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 RUSSIA
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 CHINA
  • 10.4.2 INDIA
  • 10.4.3 JAPAN
  • 10.4.4 SOUTH KOREA
  • 10.4.5 MALAYSIA
  • 10.4.6 THAILAND
  • 10.4.7 INDONESIA
  • 10.4.8 REST OF ASIA-PACIFIC
• 10.5 SOUTH AMERICA
  • 10.5.1 BRAZIL
  • 10.5.2 MEXICO
  • 10.5.3 ARGENTINA
  • 10.5.4 REST OF SOUTH AMERICA
• 10.6 MIDDLE EAST AND AFRICA
  • 10.6.1 GCC COUNTRIES
  • 10.6.2 SOUTH AFRICA
  • 10.6.3 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 COMPANY MARKET SHARE ANALYSIS, 2024 (VALUE)
• 11.3 COMPETITOR DASHBOARD
• 11.4 PUBLIC PLAYERS STOCK SUMMARY
• 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.6.1 DONATION
  • 11.6.2 AGREEMENT

12 COMPANY PROFILES

• 12.1 ANGIODYNAMICS, INC.
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT ANALYSIS
  • 12.1.6 KEY STRATEGIES
• 12.2 B. BRAUN MELSUNGEN AG
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 SWOT ANALYSIS
  • 12.2.6 KEY STRATEGIES
• 12.3 BECTON, DICKINSON AND COMPANY (BD)
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 SWOT ANALYSIS
  • 12.3.6 KEY STRATEGIES
• 12.4 COOK MEDICAL LLC
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 SWOT ANALYSIS
  • 12.4.6 KEY STRATEGIES
• 12.5 DISTRICLASS MEDICAL SA
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 VYGON
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGIES
• 12.7 SILMAG AG
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 POLY MEDICURE LTD
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 PAKUMEDMEDICAL PRODUCTS GMBH
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 SWOT ANALYSIS
  • 12.9.6 KEY STRATEGIES
• 12.10 SOPHYSA
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 SWOT ANALYSIS
  • 12.10.6 KEY STRATEGIES

13 DATA CITATIONS